| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Department of Medicine and
Department of Biochemistry, University of Wisconsin, Madison, Wisconsin, USA;
Department of Biology, San Diego State University, San Diego, California, USA; and
Department of Medicine, University of California, Los Angeles, California, USA
1Correspondence: Endocrine Section, University of Wisconsin-Madison, H4/526 Clinical Science Center, 600 Highland Ave., Madison, WI 53792, USA. E-mail: as7{at}medicine.wisc.edu
Pancreatic beta-cell loss through apoptosis represents a key factor in the pathogenesis of diabetes; however, no effective approaches to block this process and preserve endogenous beta-cell mass are currently available. To study the role of thioredoxin-interacting protein (TXNIP), a proapoptotic beta-cell factor we recently identified, we used HcB-19 (TXNIP nonsense mutation) and beta-cell-specific TXNIP knockout (bTKO) mice. Interestingly, HcB-19 mice demonstrate increased adiposity, but have lower blood glucose levels and increased pancreatic beta-cell mass (as assessed by morphometry). Moreover, HcB-19 mice are resistant to streptozotocin-induced diabetes. When intercrossed with obese, insulin-resistant, and diabetic mice, double-mutant BTBRlepob/obtxniphcb/hcb are even more obese, but are protected against diabetes and beta-cell apoptosis, resulting in a 3-fold increase in beta-cell mass. Beta-cell-specific TXNIP deletion also enhanced beta-cell mass (P<0.005) and protected against diabetes, and terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) revealed a 
50-fold reduction in beta-cell apoptosis in streptozotocin-treated bTKO mice. We further discovered that TXNIP deficiency induces Akt/Bcl-xL signaling and inhibits mitochondrial beta-cell death, suggesting that these mechanisms may mediate the beta-cell protective effects of TXNIP deficiency. These results suggest that lowering beta-cell TXNIP expression could serve as a novel strategy for the treatment of type 1 and type 2 diabetes by promoting endogenous beta-cell survival.—Chen, J., Hui, S. T., Couto, F. M., Mungrue, I. N., Davis, D. B., Attie, A. D., Lusis, A. J., Davis, R. A., Shalev, A. Thioredoxin-interacting protein deficiency induces Akt/Bcl-xL signaling and pancreatic beta-cell mass and protects against diabetes.
Key Words: apoptosis • islets • obesity • insulin sensitivity • bTKO • TXNIP
This article has been cited by other articles:
|
|
 |
|
  H. Cha-Molstad, G. Saxena, J. Chen, and A. Shalev Glucose-stimulated Expression of Txnip Is Mediated by Carbohydrate Response Element-binding Protein, p300, and Histone H4 Acetylation in Pancreatic Beta Cells J. Biol. Chem., June 19, 2009; 284(25): 16898 - 16905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Masson, S. Koren, F. Razik, H. Goldberg, E. P. Kwan, L. Sheu, H. Y. Gaisano, and I. G. Fantus High {beta}-cell mass prevents streptozotocin-induced diabetes in thioredoxin-interacting protein-deficient mice Am J Physiol Endocrinol Metab, June 1, 2009; 296(6): E1251 - E1261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chen, H. Cha-Molstad, A. Szabo, and A. Shalev Diabetes induces and calcium channel blockers prevent cardiac expression of proapoptotic thioredoxin-interacting protein Am J Physiol Endocrinol Metab, May 1, 2009; 296(5): E1133 - E1139. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
